Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Irinotecan in Treating Patients With Colorectal Cancer

This study has been terminated.
(Study terminated due to poor accrual)
National Cancer Institute (NCI)
Information provided by:
California Cancer Consortium Identifier:
First received: November 1, 1999
Last updated: February 13, 2015
Last verified: September 2013

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have colorectal cancer.

Condition Intervention Phase
Colorectal Cancer
Drug: irinotecan hydrochloride
Genetic: mutation analysis
Genetic: polymorphism analysis
Phase 2

Study Type: Observational
Official Title: UGT1A1 Polymorphism in Patients With Colorectal Cancer Treated With CPT-11 (Irinotecan)

Resource links provided by NLM:

Further study details as provided by California Cancer Consortium:

Estimated Enrollment: 28
Study Start Date: October 1998
Study Completion Date: February 2001
Primary Completion Date: February 2001 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the frequency of genetic polymorphisms of UGT1 in Hispanics with colorectal cancer.
  • Determine if pharmacokinetics of irinotecan and its metabolites, SN38 and SN38G, are associated with the genotype of UGT1 and clinical toxicity.
  • Determine whether the genetic polymorphisms of UGT1 are associated with clinical toxicity and pharmacokinetics/pharmacodynamics of irinotecan in patients with unresectable colorectal cancer treated with irinotecan.
  • Determine the response, time to progression, and survival in patients with UGT1A1 polymorphisms treated with irinotecan.

OUTLINE: Genomic DNA is isolated from blood samples from patients and analyzed for UGT1 polymorphisms. Patients are stratified according to UGT1 genotype (homozygous for wild type vs heterozygous for abnormal allele vs homozygous for abnormal allele).

Patients receive irinotecan over 90 minutes weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: Approximately 28 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically proven advanced or disseminated colorectal cancer

    • Progressive disease on fluorouracil based chemotherapy OR
    • Recurrence of disease within 12 months of adjuvant therapy with fluorouracil
  • No known CNS metastases or carcinomatous meningitis



  • 18 and over

Performance status:

  • SWOG 0-2

Life expectancy:

  • At least 12 weeks


  • Granulocyte count greater than 1500/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin at least 9.0 g/dL


  • Bilirubin no greater than 2 times upper limit of normal (ULN)
  • SGOT no greater than 3 times ULN (no greater than 5 times ULN if liver involved)


  • Creatinine no greater than 2.0 mg/dL
  • Calcium no greater than 12.0 mg/dL


  • No myocardial infarction within past 6 months
  • No congestive heart failure requiring therapy


  • No severe psychiatric disorders
  • No history of seizures


  • No active or uncontrolled infection
  • HIV negative
  • No prior malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No uncontrolled diabetes mellitus (random blood sugar 200 mg/dL or greater)
  • No other severe concurrent disease
  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • See Disease Characteristics
  • Prior oxaliplatin allowed
  • No prior irinotecan or topotecan

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified


  • No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003843

United States, California
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States, 90033-0804
University of California Davis Cancer Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
California Cancer Consortium
National Cancer Institute (NCI)
Study Chair: Heinz-Josef Lenz, MD University of Southern California
  More Information Identifier: NCT00003843     History of Changes
Other Study ID Numbers: CDR0000067003
Study First Received: November 1, 1999
Last Updated: February 13, 2015

Keywords provided by California Cancer Consortium:
stage IV colon cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 24, 2017